FDA-Cleared Elitone Incontinence Device Stops Bladder Leaks without Surgery or Medication
FEMSelect, a privately held women-led company revolutionizing women's pelvic health, today announced its expansion into the incontinence market through a strategic partnership with Elidah, developer of the clinically proven Elitone® device. Elitone®and Elitone URGE are FDA-cleared medical devices that you use at home to treat urinary incontinence.This agreement allows FEMSelect to distribute Elitone® as part of its growing women's health portfolio, marking another step in the company's mission to improve quality of life for women globally.
https://mma.prnewswire.com/media/2686133/FEMSelect_Logo.jpg
The addition of Elitone® builds on FEMSelect's flagship product, EnPlace®, the first truly minimally invasive approach to pelvic organ prolapse. Elitone and Elitone URGE send small electrical signals to the muscles and nerves that control pelvic function. Elitone safely and comfortably tones tissue for stress incontinence or relaxes for urge incontinence, better than you can on your own. With use of Elitone at home for 20 minutes a day for 6 weeks, patients can reduce unintended leaks. Pelvic organ prolapse and urinary incontinence are closely linked conditions, both stemming from pelvic floor dysfunction and often occurring together. Urinary incontinence is one of the most common – and most underreported – conditions impacting women, with nearly 1 in 3 experiencing involuntary leakage at some point in their lives.
“Our vision at FEMSelect is to build a platform of innovative solutions that address the most pressing, underserved conditions in women's health,” said Sasha Schrode, Chief Executive Officer of FEMSelect. “Elitone® is exactly the kind of breakthrough we want in our portfolio-backed by science, patient-friendly, and designed to address a massive unmet need. Together with Elidah, we can deliver this life-changing therapy to more women around the world.”
By offering solutions that address both, FEMSelect is deepening its commitment to providing more comprehensive, effective care for women and equipping healthcare providers with innovative tools that meet real, unmet needs. With EnPlace® and Elitone®, FEMSelect is creating a robust portfolio that spans treatment for conditions impacting millions of women, many of which have been overlooked or underserved for decades.
This partnership reflects FEMSelect's continued growth strategy, following its oversubscribed Series B financing and U.S. headquarters relocation earlier this year. The company is actively expanding its commercial team, building physician and patient awareness campaigns, and exploring additional portfolio additions to address conditions across screening, diagnosis, treatment, and management in women's health.
About FEMSelectFEMSelect is at the forefront of women's health, delivering innovative solutions that transform care and improve quality of life. Its lead technology, EnPlace®, is a minimally invasive approach to pelvic organ prolapse that allows most women to return home the same day. With a growing portfolio of solutions like Elitone®, FEMSelect is committed to addressing some of the most prevalent-and most underserved-conditions in women's health.
About Elidah and Elitone®Elidah is a women-led medical device company focused on non-invasive solutions for pelvic health. Its flagship product, Elitone®, is the first wearable device designed to treat stress urinary incontinence using targeted neuromuscular stimulation. FDA-cleared and backed by clinical data, Elitone® empowers women to regain control and live life without compromise.
Media Contact:Stefanie Williamson
stefanie@9thstreetpr.com
631.754.0460
https://edge.prnewswire.com/c/img/favicon.png?sn=NY82990&sd=2025-09-25
View original content to download multimedia:https://www.prnewswire.com/news-releases/femselect-expands-womens-health-portfolio-with-elidah-partnership-to-distribute-elitone-302566772.html
SOURCE FEMSelect
https://rt.newswire.ca/rt.gif?NewsItemId=NY82990&Transmission_Id=202509250800PR_NEWS_USPR_____NY82990&DateId=20250925